May is Brain Cancer Awareness Month
Please join the AACR in supporting brain cancer research
This year some 25,050 people in the United States are expected to be diagnosed with brain cancer and other nervous system cancers, according to federal statistics. These cancers make up a portion of the nearly 89,000 brain tumors that will be diagnosed in this country in 2022.
There are many types of brain and spinal cord tumors. The tumors are formed by the abnormal growth of cells and may be either benign or malignant. Benign brain and spinal cord tumors grow and press on nearby areas of the brain. They rarely spread into other tissues and may recur.
Malignant brain and spinal cord tumors are likely to grow quickly and spread into other brain tissue.
When a tumor grows into or presses on an area of the brain, it may stop that part of the brain from working the way it should. Both benign and malignant brain tumors produce signs and symptoms and need treatment.
Tumors that start in the brain are called primary brain tumors. Primary brain tumors may spread to other parts of the brain or to the spine, but rarely spread to other parts of the body. Often, tumors found in the brain have started somewhere else in the body and spread to one or more parts of the brain. These are called metastatic brain tumors.
Metastatic brain tumors are more common than primary brain tumors. About half of metastatic brain tumors are from lung cancer.
May is Brain Cancer Awareness Month.
The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program estimates that some 18,280 people in the U.S. will die from brain and other nervous system cancers in 2022.
What the AACR Is Currently Doing in the Area of Brain Cancer Research
In October 2023 the AACR will host an AACR Special Conference: Brain Cancer in Minneapolis, Minnesota.
The AACR was pleased to recognize several researchers for their work in the field of brain cancers:
- 2022 AACR-Novocure Tumor Treating Fields Research Grant: Matthew R. Sarkisian, PhD, University of Florida, “Improving TTFields efficacy by altering ciliogenesis”
- 2022 AACR-Novocure Tumor Treating Fields Research Grant: Stuart Smith, BM, BCh, PhD, University of Nottingham, United Kingdom, “Combining tumor treating fields with ion channel blockade”
- 2021 AACR-Novocure Career Development Awards for Tumor Treating Fields Research: Gerben Borst, MD, PhD, University of Manchester, “Unraveling the cell cycle effect of TTFields towards synergistic strategies”
- 2021 AACR-Novocure Tumor Treating Fields Research Grant: Spencer J. Collis, PhD, University of Sheffield, “TTFields-based DDRi combinations to overcome spatiofunctional heterogeneity”
- 2021 AACR-Novocure Tumor Treating Fields Research Grant: Chang-Young Jang, PhD, Sookmyung Women’s University, “Identification of new target of TTFs in mitosis for therapeutic application
- 2021 AACR-Novocure Tumor Treating Fields Research Grant: Sara G.M. Piccirillo, PhD, University of New Mexico, “The impact of Tumor-Treating Fields on residual disease in glioblastoma.”